Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04411823 · ClinicalTrials.gov registry record · NA

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction

A NA study of Gastroesophageal Reflux and Sleeve Gastrectomy, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
2
Study locations

NCT04411823 is a NA study of Gastroesophageal Reflux and Sleeve Gastrectomy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 200 participants, above the 177-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (13% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04411823, a NA study of Gastroesophageal Reflux and Sleeve Gastrectomy, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
2
Study locations

Study Summary

Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.

Interventions

  • DEVICE EndoFLIP measurement

Study Locations (2)

Florida

  • Orlando Health - Orlando

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-02-01
Est. Completion 2028-10
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04411823

The ClinicalTrials.gov registry entry for NCT04411823 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (13% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which EndoFLIP measurement is the first listed.

NCT04411823 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04411823 about?

NCT04411823 is a clinical study titled "Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction". Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.

What is the current status of trial NCT04411823?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2021-02-01. Estimated completion is 2028-10.

What conditions does trial NCT04411823 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux, Sleeve Gastrectomy, Bariatric Surgery Complication.

What interventions are being tested in trial NCT04411823?

The interventions under investigation include: EndoFLIP measurement (DEVICE).

Who is sponsoring clinical trial NCT04411823?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04411823 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.